Perspectives on the Treatment of Malignant Pleural Mesothelioma

Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-09, Vol.385 (13), p.1207-1218
Hauptverfasser:	Janes, Sam M, Alrifai, Doraid, Fennell, Dean A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Antineoplastic Agents - therapeutic use Asbestos Biopsy Cancer therapies Cisplatin Clinical trials Combined Modality Therapy Critical Care Critical Care General Epigenetic Repression Hematology Humans Immune checkpoint inhibitors Immunotherapy Inflammation Intubation Medical prognosis Mesothelioma Mesothelioma, Malignant - diagnosis Mesothelioma, Malignant - pathology Mesothelioma, Malignant - therapy Oncology Patients Pleura Pleura - diagnostic imaging Pleura - pathology Pleura - surgery Pleural effusion Pleural Neoplasms - diagnosis Pleural Neoplasms - pathology Pleural Neoplasms - therapy Pulmonary Radiotherapy Surgery Surgery General Treatment resistance Treatments in Oncology Ultrasonic imaging
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend survival.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMra1912719